Senzime
7.34 SEK -0.54%1 investor is following this company
Senzime is a medical technology company. The company develops technology solutions that make it possible to follow biochemical and physiological processes before, during and after surgery. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. In addition to the main services, digital systems are also offered and developed for monitoring patients' conditions during anesthesia treatment. The company's head office is located in Uppsala.
Revenue
35.75M
EBIT %
-384.22 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
SEZI
Daily low / high price
6.96 / 7.35
SEK
Market cap
878.64M SEK
Turnover
563.53K SEK
Volume
80K
Financial calendar
Interim report
2024-05-07
General meeting
2024-05-16
Interim report
2024-08-26
Interim report
2024-11-06
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Familjen Crafoord | 16.5 % | 16.5 % |
Segulah Venture AB | 10.7 % | 10.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Invitation to live presentation of Senzime’s first quarter 2024 report
Senzime tecknar sitt första GPO-avtal i USA och blir sole source supplier
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools